Abstract
Background
We describe the clinical course of children with IgA nephropathy (IgAN), diagnosed before and after the emergence of COVID-19. We hypothesized that COVID-19 vaccination and/or infection resulted in more children with IgAN to present clinically.
Methods
We conducted a retrospective cohort study of children with IgAN diagnosed on kidney biopsy from 2014–2020 (Period 1) and 2021–2022 (Period 2). Baseline characteristics, clinical presentation, investigations and treatments were compared between patients diagnosed in Period 1 and Period 2, as well as between patients with and without chronic changes on kidney biopsy. Continuous variables were compared using the Wilcoxon rank sum test. Categorical variables were compared using χ2 or Fisher exact tests.
Results
Nineteen children with IgAN were diagnosed by kidney biopsy, with 10 during Period 1 and 9 patients during Period 2 (an average of 1–2 patients/year and 4–5 patients/year in Periods 1 and 2, respectively). The most common indication for kidney biopsy is proteinuria with urine protein/creatinine ratio 1.4 (interquartile range [IQR] 1.2–9.0) vs. 0.8 (IQR 0.6–1.5) g/g (p = 0.064) at time of kidney biopsy for patients in Period 1 and 2, respectively. Clinical course was similar in both periods. No patient required acute or chronic kidney replacement therapy.
Conclusions
The rate of diagnosing children with IgAN was higher since the emergence of COVID-19, suggesting that COVID-19 may trigger an immune response responsible for IgAN, similar to other mucosal infections.
Graphical abstract
Similar content being viewed by others
Data availability
Data presented are available upon reasonable request.
References
Coppo R (2019) Pediatric IgA nephropathy in Europe. Kidney Dis (Basel) 5:182–188
Coppo R, Robert T (2020) IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol 33:1219–1229
Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S et al (2013) Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol 17:155–173
Cho BS, Hahn WH, Cheong HI, Lim I, Ko CW, Kim SY et al (2013) A nationwide study of mass urine screening tests on Korean school children and implications for chronic kidney disease management. Clin Exp Nephrol 17:205–210
Yoshikawa N, Ito H, Nakamura H (1988) IgA nephropathy in children from Japan. Clinical and pathological features. Child Nephrol Urol 9:191–199
Lévy M, Gonzalez-Burchard G, Broyer M, Dommergues JP, Foulard M, Sorez JP et al (1985) Berger’s disease in children. Natural history and outcome. Medicine (Baltimore) 64:157–180
Southwest Pediatric Nephrology Study Group (1982) A multicenter study of IgA nephropathy in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 22(6):643–652
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M et al (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014–1021
Hanna C, Herrera Hernandez LP, Bu L, Kizilbash S, Najera L, Rheault MN et al (2021) IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 100:705–706
Udagawa T, Motoyoshi Y (2022) Macroscopic hematuria in two children with IgA nephropathy remission following Pfizer COVID-19 vaccination. Pediatr Nephrol 37:1693–1694
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100(4S):S1–S276
Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J et al (2021) Updating the international IgA nephropathy prediction tool for use in children. Kidney Int 99:1439–1450
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904
Zhang YM, Zhang H (2018) Insights into the Role of Mucosal Immunity in IgA Nephropathy. Clin J Am Soc Nephrol 13:1584–1586
Zhang J, Cao J, Ye Q (2022) Renal side effects of COVID-19 vaccination. Vaccines (Basel) 10:1783
Ma Y, Xu G (2023) New-onset IgA nephropathy following COVID-19 vaccination. QJM 116:26–39
Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT et al (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139–150
Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C et al (2018) Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3:916–925
Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K et al (2011) Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 6:1301–1307
Kawasaki Y, Maeda R, Kanno S, Suzuki Y, Ohara S, Suyama K et al (2017) Long-term follow up of pediatric immunoglobulin A nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. Pediatr Int 59:41–47
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K et al (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511–517
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M et al (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10:101–109
Funding
No funds, grants, or other support was received.
Author information
Authors and Affiliations
Contributions
Esther Huimin Leow formulated the overarching research goals and aim, conducted the literature search, collected data, analyzed the data, wrote the initial draft, then reviewed and edited the manuscript. All other authors formulated the overarching research goals and aim, reviewed and edited the manuscript and provided supervision and mentorship.
Corresponding author
Ethics declarations
Disclosures
There are no disclosures.
Conflict of interest
No authors have a conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Graphical abstract
(PPTX 130 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Leow, E.H., Chong, S.L., Yap, C.J.Y. et al. IgA nephropathy in children: before and after the start of COVID-19. Pediatr Nephrol 39, 1161–1167 (2024). https://doi.org/10.1007/s00467-023-06196-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-023-06196-2